A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients

Host-directed-therapy strategies are warranted to fight tuberculosis. Here we assess the safety and immunogenicity of adjunctive vaccination with the H56:IC31 candidate and cyclooxygenase-2-inhibitor treatment (etoricoxib) in pulmonary and extra-pulmonary tuberculosis patients in a randomized open-l...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenum, Synne, Tonby, Kristian, Rueegg, Corina S., Rühwald, Morten, Kristiansen, Max P., Bang, Peter, Olsen, Inge Christoffer, Sellæg, Kjersti, Røstad, Kjerstin, Mustafa, Tehmina, Taskén, Kjetil, Kvale, Dag, Mortensen, Rasmus, Dyrhol-Riise, Anne Ma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608791/
https://www.ncbi.nlm.nih.gov/pubmed/34811370
http://dx.doi.org/10.1038/s41467-021-27029-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608791/
https://www.ncbi.nlm.nih.gov/pubmed/34811370
http://dx.doi.org/10.1038/s41467-021-27029-6

Ejemplares similares